secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001213900-24-048030
Event type: regulatory
Sentiment:  negative
Materiality: 0.78
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BiomX receives NYSE American delisting notice for equity deficiency; interim CFO departs
--------------------------------------------------------------------------------

- Stockholders' capital deficiency of $9.5M as of March 31, 2024; losses in five recent fiscal years.
- Plan to regain compliance due June 22, 2024; final compliance deadline November 23, 2025.
- Expects to reclassify $32.4M to equity via Series X Preferred conversion at July 2024 shareholder meeting.
- Common stock to trade with '.BC' designation during cure period.
- Interim CFO Avraham Gabay steps down May 31, 2024; CFO Marina Wolfson returns from maternity leave.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/0001213900-24-048030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/ea020712501-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-048030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer